For the latest industry updates and upcoming events, register for our newsletter
By Heidi Henderson, Engineered Tax Services
2013 Tax Filing ‘Window of Opportunity’
Over the past six months, the IRS has finalized the tangible property regulations in relation to the
acquisition, repair and/or disposition of tangible property (T-Regs), along with further guidance. This guidance has clarified partial disposition elections along with automatic consent for accounting method changes and elections under the final regs.[hr]
2014 Growth for CPA Firms Through Cost Segregation StudiesBy Engineered Tax Services
Cost segregation remains amongst the top niche services for growth in Accounting Today’s 2014 Top 100 Firms. You too can increase your firm’s cash flow through cost segregation services. Cost segregation is a service that increases near term cash flow by utilizing shorter recover periods to accelerate the return on capital from your investment in property. The difference is a change in deprecation from a 39 year period to 5, 7, or 15 year class lives. [hr]
Capturing the Elusive Research & Development Tax Credit
The Research and Development (R&D) Tax Credit is one of the most significant domestic tax credits serving as a substantial tool for maximizing a company’s cash flow and bottom line. Despite the fact that the R&D credit has been available since 1981, less than a third of eligible companies recognize that they qualify for the credit.[hr]
The Positive Impact of R&D on the Cystic Fibrosis Communityby Matthew Herper, Forbes
As a member of the Cystic Fibrosis Foundation, ETS would like to share the following success stories and the strides research is making for the CF community: Kalydeco, for cystic fibrosis, is a triumph of genetics and drug development, the first medicine to directly affect the genetic defect that causes the disease. It will only help 4% of the 70,000 people who suffer from declining lunch function, damaged pancreases, and shortened lives due to the CF worldwide, but in those few it has a dramatic effect. It makes medical history for three reason… Related Articles: A Trail Blazer in Research, A Model In Medicine The unique and mutually beneficial partnership that led to the approval of Kalydeco serves as a great model for what companies and patient groups can achieve if they collaborate on drug development. Continue Reading Venture Philanthropy New Cure for Deadly Diseases Bill Elder was diagnosed with cystic fibrosis at the age of 8 and thanks to the development of Kalydeco, he has been given the chance to live a long and healthy life. Here he shares his story of his challenges and how this little blue pill changed his life.
Provided by the Cystic Fibrosis Foundation, Palm Beach Chapter [hr]
[box title=”Upcoming Webinars” centered_title=”false” with_bg=”true”]Upcoming Webinar! A Practical Guide to Identifying, Gathering, and Documenting a Sustainable Research Tax Credit Claim
Wednesday, April 23rd, 2014 11:00AM-12:00PM EDT
This presentation will help you gain an understanding of the R&D Tax Credit and how it applies to many principal industries including manufacturing, professional, scientific and technical services, and information sectors. During this presentation, you will build an understanding of how these unused tax credits offered by the government, can become an additional value-added service to your clients by increasing their cash flow, as well as revenue stream for your firm.
To schedule a CPE Lunch & Learn, contact us here today![/box]